Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $4,919,250.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 75,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the sale, the insider directly owned 8,977 shares of the company’s stock, valued at approximately $588,801.43. This trade represents a 89.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Corcept Therapeutics Stock Performance

CORT opened at $69.49 on Monday. The firm has a 50 day moving average price of $48.02 and a 200 day moving average price of $52.14. The company has a market cap of $7.46 billion, a PE ratio of 198.55 and a beta of 0.50. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The business had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $0.17 EPS. On average, sell-side analysts predict that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current year.

Institutional Trading of Corcept Therapeutics

Large investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Corcept Therapeutics by 18.9% during the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 2,444 shares in the last quarter. Amundi acquired a new stake in shares of Corcept Therapeutics during the first quarter worth approximately $450,000. NewEdge Advisors LLC acquired a new stake in shares of Corcept Therapeutics during the first quarter worth approximately $518,000. EverSource Wealth Advisors LLC grew its position in shares of Corcept Therapeutics by 273.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock worth $106,000 after buying an additional 1,055 shares in the last quarter. Finally, Marshall Wace LLP grew its position in shares of Corcept Therapeutics by 795.3% during the second quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock worth $3,391,000 after buying an additional 41,040 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright increased their price objective on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research report on Thursday. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.